AN2 TherapeuticsANTX
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 45 institutions reported holding AN2 Therapeutics Inc. (ANTX) in their 13F filings, down 9 from Q1 2024. 6 opened new positions and 14 sold out. The largest holders were Ra Capital Management, L.P. ($11.9M), Octagon Capital Advisors LP ($6.9M) and Frazier Life Sciences Management, L.P. ($4.5M). 3 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio), Israel Englander (0.0% of Millennium Management's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- AN2 Therapeutics Inc.
- CUSIP
- 037326105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $403K |
| Exits | 14 | $8.9M |
All 13F filers, Q1 2024 → Q2 2024: 3,836,066 shares bought and 3,127,091 shares sold, net +708,975 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 45 holders
| Ra Capital Management, L.P. | 0.16% | No change | 5,551,295 | $11.9M |
| Octagon Capital Advisors LP | 1.14% | Add +191.9% | 3,220,263 | $6.9M |
| Frazier Life Sciences Management, L.P. | 0.21% | Add +50.4% | 2,088,889 | $4.5M |
| TCG Crossover Management, LLC | 0.35% | No change | 1,555,118 | $3.3M |
| Citadel Advisors | 0.00% | Reduce -0.2% | 1,553,829 | $3.3M |
| Janus Henderson Group PLC | 0.00% | Reduce -0.0% | 1,221,051 | $2.6M |
| Vanguard Group Inc. | 0.00% | Reduce -0.6% | 1,041,527 | $2.2M |
| Millennium Management | 0.00% | Add +443.1% | 526,352 | $1.1M |
| Adage Capital Partners Gp, L.L.C. | 0.00% | No change | 312,615 | $672K |
| BlackRock Inc. | 0.00% | Add +3.0% | 299,703 | $644K |
| Goldman Sachs Group Inc. | 0.00% | Add +690.2% | 224,185 | $482K |
| Ghost Tree Capital, LLC | 0.16% | No change | 219,331 | $472K |
| Geode Capital Management, LLC | 0.00% | Add +0.9% | 180,923 | $389K |
| Two Sigma Advisers, LP | 0.00% | New | 134,700 | $290K |
| Two Sigma Investments, LP | 0.00% | Add +40.3% | 132,088 | $284K |
| Bridgeway Capital Management, LLC | 0.01% | Add +296.7% | 104,292 | $224K |
| Alyeska Investment Group, L.P. | 0.00% | No change | 100,000 | $215K |
| Nantahala Capital Management, LLC | 0.02% | No change | 98,278 | $211K |
| Squarepoint Ops LLC | 0.00% | Add +95.7% | 97,063 | $209K |
| Marshall Wace, LLP | 0.00% | Add +16.5% | 96,111 | $207K |
| Walleye Capital LLC | 0.00% | Reduce -30.4% | 92,406 | $199K |
| Acadian Asset Management LLC | 0.00% | Reduce -46.8% | 86,948 | $185K |
| State Street Corp. | 0.00% | No change | 60,302 | $130K |
| Curi Capital, LLC | 0.00% | No change | 45,942 | $99K |
| Prelude Capital Management, LLC | 0.01% | Reduce -3.4% | 38,918 | $84K |
| Citigroup Inc. | 0.00% | Reduce -46.5% | 37,887 | $81K |
| Occudo Quantitative Strategies LP | 0.01% | Reduce -6.2% | 35,366 | $76K |
| Northern Trust Corp. | 0.00% | Reduce -10.4% | 32,595 | $70K |
| Susquehanna International Group, LLP | 0.00% | Reduce -84.6% | 31,245 | $67K |
| Captrust Financial Advisors | 0.00% | No change | 28,667 | $62K |
| Dimensional Fund Advisors LP | 0.00% | Reduce -34.0% | 25,150 | $54K |
| Private Advisor Group, LLC | 0.00% | No change | 22,500 | $48K |
| Schonfeld Strategic Advisors LLC | 0.00% | New | 21,774 | $47K |
| UBS Group AG | 0.00% | Reduce -10.7% | 17,483 | $38K |
| Morgan Stanley | 0.00% | Add +319.3% | 17,461 | $38K |
| Bank of America Corp. | 0.00% | Add +4.4% | 15,636 | $34K |
| Renaissance Technologies | 0.00% | New | 14,300 | $31K |
| Cubist Systematic Strategies, LLC | 0.00% | New | 12,825 | $28K |
| Qube Research & Technologies Ltd | 0.00% | Reduce -79.8% | 10,186 | $22K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +385.7% | 5,406 | $12K |
| Royal Bank of Canada | 0.00% | New | 2,812 | $6K |
| JPMorgan Chase & Co. | 0.00% | New | 1,020 | $2K |
| Federated Hermes, Inc. | 0.00% | Add +334.6% | 917 | $2K |
| Osaic Holdings, Inc. | 0.00% | No change | 300 | $645 |
| Rhumbline Advisers | 0.00% | No change | 250 | $537 |
"% of holder's portfolio" is ANTX's weight in each manager's 13F, not the share of AN2 Therapeutics Inc. the manager owns.